These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26324672)

  • 1. A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study.
    Ogawa H; Soejima H; Matsui K; Kim-Mitsuyama S; Yasuda O; Node K; Yamamuro M; Yamamoto E; Kataoka K; Jinnouchi H; Sekigami T;
    Eur J Prev Cardiol; 2016 Jun; 23(9):913-21. PubMed ID: 26324672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
    Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.
    Vogt L; Navis G; Köster J; Manolis AJ; Reid JL; de Zeeuw D;
    J Hypertens; 2005 Nov; 23(11):2055-61. PubMed ID: 16208149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A third amlodipine/ARB combination (Twynsta) for hypertension.
    Med Lett Drugs Ther; 2010 Jan; 52(1329):2-3. PubMed ID: 20208469
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of two fixed-dose combinations of S-amlodipine and telmisartan (CKD-828) versus S-amlodipine monotherapy in patients with hypertension inadequately controlled using S-amlodipine monotherapy: an 8-week, multicenter, randomized, double-blind, Phase III clinical study.
    Ihm SH; Jeon HK; Cha TJ; Hong TJ; Kim SH; Lee NH; Yoon JH; Yoon N; Hwang KK; Jo SH; Youn HJ
    Drug Des Devel Ther; 2016; 10():3817-3826. PubMed ID: 27920497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
    Suzuki H; Kanno Y; Sugahara S; Ikeda N; Shoda J; Takenaka T; Inoue T; Araki R
    Am J Kidney Dis; 2008 Sep; 52(3):501-6. PubMed ID: 18653268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.
    Lake JE; Seang S; Kelesidis T; Liao DH; Hodis HN; Stein JH; Currier JS
    HIV Clin Trials; 2015 Oct; 16(5):197-206. PubMed ID: 26360501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials.
    Takagi H; Yamamoto H; Iwata K; Goto SN; Umemoto T;
    Int J Cardiol; 2013 Aug; 167(4):1443-9. PubMed ID: 22560941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
    Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
    Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients.
    Hasegawa H; Takano H; Narumi H; Ohtsuka M; Mizuguchi T; Namiki T; Kobayashi Y; Komuro I
    Hypertens Res; 2011 Nov; 34(11):1179-84. PubMed ID: 21796128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term follow-up of cardiovascular risk markers in patients with hypertension. Rationale, design, and baseline characteristics of the i-Search Plus Registry].
    Tebbe U; Lüders S; de Haan F; Bramlage P; Böhm M; Thoenes M; Paar WD; Schrader J;
    Med Klin (Munich); 2007 Oct; 102(10):824-32. PubMed ID: 17928966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 17. New data on ONTARGET: more confusion?
    Escobar C; Echarri R; Barrios V
    J Clin Hypertens (Greenwich); 2010 Mar; 12(3):199. PubMed ID: 20433538
    [No Abstract]   [Full Text] [Related]  

  • 18. Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial.
    Kim-Mitsuyama S; Soejima H; Yasuda O; Node K; Jinnouchi H; Yamamoto E; Sekigami T; Ogawa H; Matsui K
    Hypertens Res; 2019 Jun; 42(6):883-891. PubMed ID: 30664702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
    Sharma A; Baliga V;
    J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.